Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02108860
Other study ID # ABROGATE 5527
Secondary ID 2013-005535-24U5
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date April 25, 2015
Est. completion date September 2023

Study information

Verified date August 2023
Source University of South Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe granulomatosis with polyangiitis (Wegener's) (GPA) . Participants will be randomized 1:1 to receive either abatacept 125 mg or placebo administered by subcutaneous injection once a week. Participants will continue on study treatment for a minimum of 12 months unless they experience a disease relapse or disease flare. Participants who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept.


Description:

Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe GPA. Patients who enter the trial will be maintained on a stable dose of their maintenance immunosuppressive agent which may include methotrexate (MTX), azathioprine (AZA), or mycophenolate (MA) and will undergo a blinded randomization to receive abatacept or placebo. Patients will additionally receive prednisone 30 mg daily that will then be tapered to zero using a standardized tapering schedule. If an enrolled patient experiences a non-severe relapse or non-severe disease worsening though common closing, or if they have not achieved remission by month 6, they will have the option of entering an open-label trial period whereby they would receive abatacept in conjunction with their maintenance immunosuppressive and a standardized glucocorticoid taper. Patients with a severe disease relapse or severe disease worsening will have met criteria for early termination criteria and be removed from active study treatment. Patients will remain on study until reaching criteria for early termination or until common closing, 12 months after randomization of the final patient. After common closing or early termination, patients will be treated with best medical judgment and will undergo a post-treatment safety visit 3 months after coming off of study treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 65
Est. completion date September 2023
Est. primary completion date July 25, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: 1. Patients must be considered as being best characterized as GPA and not microscopic polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (EGPA) and must have met at least 2 of the 5 modified ACR classification criteria for GPA. These do not need to be present at the time of study entry. The modified ACR criteria are: 1. Nasal or oral inflammation, defined as the development of painful or painless oral ulcers or purulent or bloody nasal discharge 2. Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates, or cavities 3. Active urinary sediment, defined as microscopic hematuria (>5 red blood cells per high power field) or red blood cell casts 4. Granulomatous inflammation on biopsy, defined as histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area (artery or arteriole) 5. Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3 or myeloperoxidase measured by enzyme-linked immunoassay 2. Relapse of GPA within the 28 days prior to screening where the active disease features meet the following definition of non-severe disease: 1. No disease manifestations that would be scored as a major element in the BVAS/WG 2. Absence of any disease feature that poses an immediate threat to either a critical individual organ or the patient's life 3. Age 15 and older 4. Willing and able to comply with treatment and follow-up procedures 5. Both women and men must be willing to use an effective means of birth control while receiving treatment through this study. Women should continue the use of an effective means of birth control for a minimum of 14 weeks after the last dose of study drug. Effective contraception methods include abstinence, oral contraceptives (birth control pills), IUD, diaphragm, Norplant, approved hormone injections, condoms, or medical sterilization. If applicable, participating sites will defer to their local authorities if they require stricter guidelines on the types of allowable contraception methods. 6. Willing and able to provide written informed consent (and written assent of minor participants if applicable.) Exclusion Criteria: 1. Presence of involvement that does not meet the criteria for non-severe disease 2. Treatment with CYC within 3 months prior to screening 3. Treatment with methylprednisolone 1000 mg within 28 days prior to enrollment 4. Treatment with prednisone or prednisolone> 30 mg/day for > 28 days immediately prior to study entry 5. Initiation or dose increase of the maintenance immunosuppressive agent (MTX, AZA, MA) within 3 months prior to screening 6. Evidence of active infection (includes chronic infection) 7. Patients who are pregnant or who are nursing 8. Known infection with human immunodeficiency virus (HIV), hepatitis C, or a positive hepatitis B surface antigen 9. Inability to comply with study guidelines 10. Cytopenia: platelet count < 100,000/mm3, white blood cell count (WBC) < 3,000/mm3 (3 x 109/L), absolute neutrophil count < 1500/mm3, hemoglobin (Hgb) < 8.5 g/dL 11. Chronic renal insufficiency defined by a creatinine clearance of less than or equal to 20 ml/min 12. AST or ALT > 3 times above the upper limit of the normal laboratory range 13. Known current use of illegal drugs 14. Other uncontrolled disease (co-morbidity) that could prevent a patient from fulfilling the study requirements or that would substantially increase the risk of study procedures 15. History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure 16. Receipt of an investigational agent or device within 30 days prior to enrollment or 5 half lives of the investigational drug (whichever is longer) 17. A live vaccination fewer than 3 months before enrollment 18. Current clinical, radiographic, or laboratory evidence of active tuberculosis 19. A history of active tuberculosis within the past 3 years even if treated 20. A history of active tuberculosis greater than 3 years ago unless there is documentation of prior anti-tuberculosis treatment of appropriate duration and type 21. Latent tuberculosis unless there is documentation of prior anti-tuberculosis treatment of appropriate duration and type 22. Latent tuberculosis currently being treated with isoniazid (INH) or other therapy for latent tuberculosis given according to local health authority guidelines (e.g., Center for Disease Control (CDC)) who have received such therapy for 4 weeks or less prior to randomization (Day 1). Subjects with a positive tuberculosis screening test indicative of latent tuberculosis will be eligible for the study if they have no evidence of current tuberculosis on chest xray at screening and they are actively being treated for tuberculosis with INH or other therapy for latent tuberculosis given according to local health authority guidelines (e.g., CDC) that has been given for at least 4 weeks prior to randomization (Day 1). These subjects must complete treatment according to local health authority guidelines. 23. History of herpes zoster that resolved less than 2 months prior to enrollment 24. Treatment with rituximab or any other biologic B cell depleting agent within the past 6 months 25. Treatment with alemtuzumab or anti-thymocyte globulin within the last 12 months 26. Treatment with intravenous immunoglobulin given at an immunomodulatory dosage or plasma exchange within the past 3 months. Patients can be enrolled if they are otherwise eligible and receiving immunoglobulin replacement for hypogammaglobulinemia. 27. Treatment with infliximab, etanercept, adalimumab, tocilizumab, or any other biologic agent within the past 3 months or 5 half lives of the agent (whichever is longer)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Abatacept
Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
placebo
Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.

Locations

Country Name City State
Canada University of Calgary Calgary Alberta
Canada St. Joseph's Hospital, Hamilton Hamilton Ontario
Canada Mount Sinai Hospital, Toronto Toronto Ontario
Canada University of British Columbia, St. Paul's Rheumatology Clinic Vancouver British Columbia
Germany Medius Kliniken Kirchheim unter Teck
Ireland St. Vincent's University Hospital Dublin
United Kingdom University of Aberdeen Aberdeen
United Kingdom University of Cambridge- Addenbrookes Hospital Cambridge
United Kingdom Nottingham University Hospitals Nottingham
United Kingdom Royal Berkshire Hospital Reading
United States University of Michigan Ann Arbor Michigan
United States Cleveland Clinic Cleveland Ohio
United States University of Kansas Medical Center Kansas City Kansas
United States Cedars Sinai Medical Center, Los Angeles Los Angeles California
United States Vanderbilt University Nashville Tennessee
United States Hospital for Special Surgery New York New York
United States University of Pennsylvania Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Rochester Rochester Minnesota
United States University of South Florida Rheumatology Tampa Florida

Sponsors (6)

Lead Sponsor Collaborator
University of South Florida Bristol-Myers Squibb, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), The Cleveland Clinic, University of Pennsylvania

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Ireland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ability of abatacept to reduce the treatment failure rate Treatment failure will be defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) = 0 or 1 by 6 months.
Relapse will be defined as any of the following after remission: an increase in BVAS/WG, development of a new BVAS/WG item, or symptoms/signs of GPA that cannot be attributed to any cause other than GPA and that requires institution or dosage increase of prednisone.
Disease worsening will be defined as any of the following prior to remission: an increase in BVAS/WG, development of a new BVAS/WG item, or symptoms/signs of GPA that cannot be attributed to any cause other than GPA and that requires institution or dosage increase of prednisone.
12 months
Secondary Duration of glucocorticoid-free periods Effect of abatacept on increasing duration of glucocorticoid-free periods for participants. Patients will be treated with abatacept for a minimum of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient. 12 months
Secondary Severity of relapses in those treated with abatacept versus placebo Severity of GPA disease relapses in those treated with abatacept versus placebo. Patients will be treated with abatacept for a minimum of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient. 12 months
Secondary Health-related quality of life in those treated with abatacept versus placebo Health-related quality of life in those treated with abatacept versus placebo as assessed using the SF-36 and PROMIS questionnaires. Patients will be treated with abatacept for a minimum of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient. 12 months
Secondary Prevention of disease- or treatment-related damage with abatacept versus placebo Prevention of disease or treatment related damage as assessed by the infection rate in both treatment arms. Patients will be treated with abatacept for a minimum of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient. 12 months
Secondary Safety of abatacept in GPA Safety of abatacept in patients with GPA as assessed by reported adverse events. Patients will be treated with abatacept for a minimum of 12 months unless they reach study criteria for early termination or until common closing. Common closing will be 12 months after randomization of the final patient. 12 months
See also
  Status Clinical Trial Phase
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT00072592 - An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Phase 1
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Completed NCT01167491 - Study of One Protein Implicated in Wegener Disease N/A
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT00001473 - Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides N/A
Terminated NCT01408836 - Plasma Exchange for Renal Vasculitis Phase 2/Phase 3
Completed NCT00001256 - Steroids and Methotrexate to Treat Systemic Vasculitis Phase 2
Completed NCT00040248 - Daclizumab to Treat Wegener's Granulomatosis Phase 2
Completed NCT00005007 - Etanercept for Wegener's Granulomatosis Phase 2/Phase 3
Completed NCT00307671 - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Phase 4
Completed NCT01988506 - Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Phase 2
Recruiting NCT01066208 - American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis N/A
Completed NCT00104299 - Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Phase 2/Phase 3
Completed NCT00753103 - Anti-Cytokine Therapy for Vasculitis Phase 2
Completed NCT02176070 - Reproductive Health in Men and Women With Vasculitis N/A
Completed NCT00468208 - Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Phase 1/Phase 2
Completed NCT00004567 - Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes Phase 2
Completed NCT00001901 - Etanercept to Treat Wegener's Granulomatosis Phase 2